What is Centogene?
Centogene N.V. operates as a specialized provider of pharmaceutical solutions and diagnostic testing, serving a global clientele across Europe, the Middle East, and the Americas. The company distinguishes itself through its integrated multiomic approach, exemplified by the CENTOGENE MOx 2.0 platform, which synthesizes DNA, RNA, and biochemical testing to provide comprehensive diagnostic clarity. Beyond its laboratory capabilities, Centogene offers a suite of digital tools, including the CentoCloud SaaS platform and the FilterTool for genetic interpretation, which empower physicians and pharmaceutical partners to navigate the complexities of rare disease diagnostics with greater precision and speed.
How much funding has Centogene raised?
Centogene has raised a total of $146M across 4 funding rounds:
Series A
$28M
Stock Offering
$56M
Share Placement
$17M
Debt
$45M
Series A (2017): $28M with participation from Careventures, Deutsche Private Equity, and TVM Capital
Stock Issuance/Offering (2019): $56M led by Undisclosed
Share Placement (2022): $17M supported by Deutsche Private Equity, Careventures, and TVM Capital
Debt (2022): $45M featuring Oxford Finance
Key Investors in Centogene
Deutsche Private Equity
DPE Deutsche Private Equity is an independent German investment firm focusing on mid-sized companies in the German-speaking region that operate in industries providing long-term growth prospects.
Careventures
Careventures is an independent pan-European private equity firm dedicated to improving healthcare through smart investments and partnering with middle-market healthcare companies.
TVM Capital
TVM Capital Life Science is a transatlantic venture capital firm focused on investing in innovative life science products, diagnostics, and digital health solutions.
What's next for Centogene?
With the recent strategic investment, Centogene is well-positioned to scale its diagnostic infrastructure and expand its footprint in the pharmaceutical research market. The company's forward-looking strategy focuses on the integration of its next-generation sequencing assays into broader clinical workflows, thereby shortening the diagnostic odyssey for patients suffering from rare conditions. By leveraging its proprietary data assets and cloud-based analytical tools, Centogene aims to deepen its partnerships with biopharmaceutical firms, ultimately facilitating the development of targeted therapies and improving patient outcomes on a global scale.
See full Centogene company page
